Follow
Lisa Salvatore
Lisa Salvatore
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Verified email at policlinicogemelli.it
Title
Cited by
Cited by
Year
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
9892014
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
6542009
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
2952008
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ...
The lancet oncology 11 (9), 845-852, 2010
2942010
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ...
European journal of cancer 50 (1), 57-63, 2014
2162014
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ...
Journal of the National Cancer Institute 103 (1), 21-30, 2011
2052011
First-line chemotherapy for mCRC—a review and evidence-based algorithm
C Cremolini, M Schirripa, C Antoniotti, R Moretto, L Salvatore, G Masi, ...
Nature reviews Clinical oncology 12 (10), 607-619, 2015
1632015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results …
C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ...
Annals of oncology 26 (6), 1188-1194, 2015
1632015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini, L Fornaro, ...
Annals of Oncology 26 (4), 724-730, 2015
1632015
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
M Schirripa, C Cremolini, F Loupakis, M Morvillo, F Bergamo, F Zoratto, ...
International journal of cancer 136 (1), 83-90, 2015
1392015
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study
D Santini, M Tampellini, B Vincenzi, T Ibrahim, C Ortega, V Virzi, ...
Annals of oncology 23 (8), 2072-2077, 2012
1332012
Genetic modulation of the let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ...
The pharmacogenomics journal 10 (5), 458-464, 2010
1302010
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial …
A Falcone, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
Journal of Clinical Oncology 31 (15_suppl), 3505-3505, 2013
1162013
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic …
R Moretto, C Cremolini, D Rossini, F Pietrantonio, F Battaglin, A Mennitto, ...
The oncologist 21 (8), 988-994, 2016
1112016
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, ...
British journal of cancer 104 (8), 1262-1269, 2011
1112011
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the …
L Fornaro, S Lonardi, G Masi, F Loupakis, F Bergamo, L Salvatore, ...
Annals of oncology 24 (8), 2062-2067, 2013
1052013
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer
V Catalano, F Loupakis, F Graziano, R Bisonni, U Torresi, B Vincenzi, ...
Annals of oncology 23 (1), 135-141, 2012
912012
Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a …
C Cremolini, C Antoniotti, S Lonardi, G Aprile, F Bergamo, G Masi, ...
JAMA oncology 4 (4), 529-536, 2018
842018
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
F Loupakis, A Ruzzo, L Salvatore, C Cremolini, G Masi, P Frumento, ...
BMC cancer 11 (1), 1-9, 2011
822011
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
F Loupakis, E Bria, V Vaccaro, F Cuppone, M Milella, P Carlini, ...
journal of experimental & clinical cancer research 29 (1), 1-8, 2010
802010
The system can't perform the operation now. Try again later.
Articles 1–20